|
1
|
Ren R: Mechanisms of BCR-ABL in the
pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer.
5:172–183. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stella S, Tirrò E, Conte E, Stagno F, Di
Raimondo F, Manzella L and Vigneri P: Suppression of survivin
induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes
imatinib-resistant CML cells to different cytotoxic drugs. Mol
Cancer Ther. 12:1085–1098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ishii Y, Nhiayi MK, Tse E, Cheng J,
Massimino M, Durden DL, Vigneri P and Wang JY: Knockout serum
replacement promotes cell survival by preventing BIM from inducing
mitochondrial cytochrome C release. PLoS One. 10:e01405852015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Manzella L, Tirrò E, Pennisi MS, Massimino
M, Stella S, Romano C, Vitale SR and Vigneri P: Roles of interferon
regulatory factors in chronic myeloid leukemia. Curr Cancer Drug
Targets. 16:594–605. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Preyer M, Vigneri P and Wang JY: Interplay
between kinase domain autophosphorylation and F-actin binding
domain in regulating imatinib sensitivity and nuclear import of
BCR-ABL. PLoS One. 6:e170202011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Giallongo C, Tibullo D, La Cava P, Branca
A, Parrinello N, Spina P, Stagno F, Conticello C, Chiarenza A,
Vigneri P, et al: BRIT1/MCPH1 expression in chronic myeloid
leukemia and its regulation of the G2/M checkpoint. Acta Haematol.
126:205–210. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stagno F, Stella S, Spitaleri A, Pennisi
MS, Di Raimondo F and Vigneri P: Imatinib mesylate in chronic
myeloid leukemia: Frontline treatment and long-term outcomes.
Expert Rev Anticancer Ther. 16:273–278. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hochhaus A, Larson RA, Guilhot F, Radich
JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F,
Fujihara S, et al: Long-term outcomes of imatinib treatment for
chronic myeloid leukemia. N Engl J Med. 376:917–927. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hochhaus A, Rosti G, Cross NC, Steegmann
JL, le Coutre P, Ossenkoppele G, Petrov L, Masszi T, Hellmann A,
Griskevicius L, et al: Frontline nilotinib in patients with chronic
myeloid leukemia in chronic phase: Results from the European
ENEST1st study. Leukemia. 30:57–64. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cortes JE, Saglio G, Kantarjian HM,
Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L,
Bradley-Garelik B, et al: Final 5-year study results of DASISION:
The dasatinib versus imatinib study in treatment-naïve chronic
myeloid leukemia patients trial. J Clin Oncol. 34:2333–2340. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stagno F, Vigneri P, Cupri A, Stella S and
Di Raimondo F: Personalized strategies for CML patients considering
discontinuation of tyrosine kinase inhibitors treatment. Leuk Res.
36:1208–1209. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cortes JE, Gambacorti-Passerini C,
Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N,
Milojkovic D, le Coutre P, et al: Bosutinib versus imatinib for
newly diagnosed chronic myeloid leukemia: Results from the
randomized BFORE trial. J Clin Oncol. 36:231–237. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stagno F, Vigneri P, Del Fabro V, Stella
S, Cupri A, Massimino M, Consoli C, Tambè L, Consoli ML, Antolino
A, et al: Influence of complex variant chromosomal translocations
in chronic myeloid leukemia patients treated with tyrosine kinase
inhibitors. Acta Oncol. 49:506–508. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Laurent E, Talpaz M, Kantarjian H and
Kurzrock R: The BCR gene and philadelphia chromosome-positive
leukemogenesis. Cancer Res. 61:2343–2355. 2001.PubMed/NCBI
|
|
15
|
Burmeister T and Reinhardt R: A multiplex
PCR for improved detection of typical and atypical BCR-ABL fusion
transcripts. Leuk Res. 32:579–585. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gui X, Zhang Y, Pan J, Qiu H, Cen J, Xue
Y, Chen S, Shen H, Yao L, Zhang J, et al: Chronic myeloid leukemia
with e14a3 BCR-ABL transcript: Analysis of characteristics and
prognostic significance. Leuk Lymphoma. 56:3343–3347. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chisti MM and Sanders DS: Chronic myeloid
leukemia with b3a3 (e14a3) fusion: A rare BCR/ABL rearrangement
presenting with thrombocytosis-does MTHFR polymorphism matter. Case
Rep Oncol. 11:485–492. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cross NCP: Detection of BCR-ABL in
hematological malignancies by RT-PCR. Methods Mol Med. 6:25–36.
1996.PubMed/NCBI
|
|
19
|
Vigneri P, Stagno F, Stella S, Cupri A,
Forte S, Massimino M, Antolino A, Siragusa S, Mannina D, Impera SS,
et al: High BCR-ABL/GUSIS levels at diagnosis of chronic
phase CML are associated with unfavorable responses to
standard-dose imatinib. Clin Cancer Res. 23:7189–7198. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vella V, Puppin C, Damante G, Vigneri R,
Sanfilippo M, Vigneri P, Tell G and Frasca F: DeltaNp73alpha
inhibits PTEN expression in thyroid cancer cells. Int J Cancer.
124:2539–2548. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jinawath N, Norris-Kirby A, Smith BD,
Gocke CD, Batista DA, Griffin CA and Murphy KM: A rare e14a3 (b3a3)
BCR-ABL fusion transcript in chronic myeloid leukemia: Diagnostic
challenges in clinical laboratory practice. J Mol Diagn.
11:359–363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Massimino M, Consoli ML, Mesuraca M,
Stagno F, Tirrò E, Stella S, Pennisi MS, Romano C, Buffa P, Bond
HM, et al: IRF5 is a target of BCR-ABL kinase activity and reduces
CML cell proliferation. Carcinogenesis. 35:1132–1143. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu LH, Pu LF, Yang DD, Zhang C, Wang HP,
Ding YY, Li MM, Zhai ZM and Xiong S: How to detect the rare BCR-ABL
(e14a3) transcript: A case report and literature review. Oncol
Lett. 14:5619–5623. 2017.PubMed/NCBI
|
|
24
|
Cai H, Yang L, Shen K, Zhang W, Xiong J,
Zhang M, Mao X, Wang Y and Xiao M: A rare e14a3 BCR/ABL fusion
transcript in acute lymphoblastic leukemia patient treated with
CAR-modified T-cell therapy. Oncol Lett. 15:2491–2494.
2018.PubMed/NCBI
|
|
25
|
Buffa P, Romano C, Pandini A, Massimino M,
Tirrò E, Di Raimondo F, Manzella L, Fraternali F and Vigneri PG:
BCR-ABL residues interacting with ponatinib are critical to
preserve the tumorigenic potential of the oncoprotein. FASEB J.
28:1221–1236. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Massimino M, Stella S, Tirrò E, Romano C,
Pennisi MS, Puma A, Manzella L, Zanghì A, Stagno F, Di Raimondo F
and Vigneri P: Non ABL-directed inhibitors as alternative treatment
strategies for chronic myeloid leukemia. Mol Cancer. 17:562018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yao J, Douer D, Wang L, Arcila ME, Nafa K
and Chiu A: A case of acute myeloid leukemia with e6a2 BCR-ABL
fusion transcript acquired after progressing from chronic
myelomonocytic leukemia. Leuk Res Rep. 7:17–19. 2017.PubMed/NCBI
|
|
28
|
Cayuela JM, Rousselot P, Nicolini F,
Espinouse D, Ollagnier C, Bui-Thi MH, Chabane K, Raffoux E,
Callet-Bauchu E, Tigaud I, et al: Identification of a rare e8a2
BCR-ABL fusion gene in three novel chronic myeloid leukemia
patients treated with imatinib. Leukemia. 19:2334–2336. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stagno F, Vigneri P, Consoli ML, Cupri A,
Stella S, Tambè L, Massimino M, Manzella L and Di Raimondo F:
Hyperdiploidy associated with a high BCR-ABL transcript level may
identify patients at risk of progression in chronic myeloid
leukemia. Acta Haematol. 127:7–9. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fujisawa S, Nakamura S, Naito K, Kobayashi
M and Ohnishi K: A variant transcript, e1a3, of the minor BCR-ABL
fusion gene in acute lymphoblastic leukemia: Case report and review
of the literature. Int J Hematol. 87:184–188. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Snyder DS, McMahon R, Cohen SR and Slovak
ML: Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: Benign
course responsive to imatinib with an RT-PCR advisory. Am J
Hematol. 75:92–95. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Smith KM, Yacobi R and Van Etten RA:
Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell.
12:27–37. 2003. View Article : Google Scholar : PubMed/NCBI
|
